DJIA 17,712.61 -45.30 -0.26%
NASDAQ 4,997.68 -15.45 -0.31%
S&P 500 2,073.25 -4.17 -0.20%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

47.75 -0.07 (-0.15%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SGEN $47.75 -0.15%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $48.00
Previous Close $47.82
Daily Range $47.52 - $48.67
52-Week Range $30.05 - $49.84
Market Cap $6.0B
P/E Ratio -72.45
Dividend (Yield) $0.00 (0.0%)
Volume 497,964
Average Daily Volume 865,767
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog

3 Stocks Improving Performance Of The Drugs Industry

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Seattle Genetics Larger Than S&P 500 Component Tenet Healthcare

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Program

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

See More SGEN News...

SGEN's Top Competitors

SGEN $47.75 (-0.15%)
Current stock: SGEN
AMGN $153.27 (-1.11%)
Current stock: AMGN
GILD $115.14 (-0.75%)
Current stock: GILD
BIIB $403.80 (-0.40%)
Current stock: BIIB